Mechanism and Clinical Translation of BCL-2–Targeted Antitumor Therapy
DOI:
https://doi.org/10.54097/5q155127Keywords:
BCL-2, Oncogenic Dependence, BH3 Mimics, Anti-apoptotic Proteins, Resistance MechanismsAbstract
The BCL-2 protein family plays a critical role in the process of apoptosis. By regulating the mitochondrial pathway, it directly influences cell survival and is of vital importance in tumorigenesis and tumor progression. Overly high level of anti-apoptotic proteins is expressed in tumor cells, including BCL-2, BCL-XL and MCL-1. Consequently, mitochondrial-mediated cell death is effectively blocked, allowing tumor cells to survive exposure to chemotherapy or targeted therapies. The reliance of cancer cells on BCL-2 proteins to sustain viability serves both as a key mechanism driving tumor progression and as an attractive focus for targeted therapeutic strategies. In recent years, a series of BH3 mimics and selective BCL-2 inhibitors, represented by Venetoclax, have been developed by scientists, and those drugs have been proved noticable effectiveness in providing treatment for tumors like Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and lymphoma. However, the degree of dependence on anti-apoptotic proteins varies significantly among different tumors, and resistance mechanisms are complex. Some tumors exhibit elevated level of BCL-XL or MCL-1 expression, while signaling pathways, such as PI3K/AKT/MAPK, enable others to survive, and still others involve the loss of function of BAX or BAD. This article summarizes the expression patterns and dependency characteristics of BCL-2 in common tumors and analyzes its role in carcinogenesis, treatment efficacy, and how drug resistance develops and eventually comes into form, with the aim of providing guidance for the clinical application of BH3 mimics and other targeted therapies.
Downloads
References
[1] Singh, R., Letai, A., & Sarosiek, K. (2019). Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nature Reviews Molecular Cell Biology, 20, 175–193. https://doi.org/10.1038/s41580-018-0089-y.
[2] Vogler, M., Walter, H. S., & Dyer, M. J. S. (2017). Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment. British Journal of Haematology, 178, 364–379. https://doi.org/ 10.1111/ bjh. 14775.
[3] Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183–192. https://doi.org/10.1016/S1535-6108(02)00127-5.
[4] Green, D. R. (2022). A matter of life and death. Cold Spring Harbor Perspectives in Biology, 14(11), a041004. https://doi. org/ 10.1101/cshperspect. a041004.
[5] Delbridge, A. R. D., Grabow, S., & Strasser, A. (2016). Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies. Nature Reviews Cancer, 16, 99–109. https:// doi.org/10.1038/nrc.2015.17.
[6] Montero, J., & Letai, A. (2018). Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death & Differentiation, 25, 56–64. https://doi.org/10. 1038/ cdd. 2017. 177.
[7] Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., Croce, C. M. (1984). Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation. Science, 226 (4687), 1097–1099. https://doi.org/10.1126/ science. 6093293.
[8] Ramesh, P., & Medema, J. P. (2020). BCL-2 family deregulation in colorectal cancer: Potential for BH3 mimetics in therapy. Apoptosis, 25, 305–320. https://doi.org/10.1007/ s10495-020-01689-9.
[9] Zhang, H., Xue, J., Hessler, P., et al. (2015). Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer. Molecular Cancer, 14, 126. https://doi.org/10.1186/s12943-015-0396-4.
[10] Roberts, A. W., Davids, M. S., Pagel, J. M., et al. (2016). Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine, 374(4), 311–322. https://doi.org/10.1056/NEJMoa1513257.
[11] Xie, H. J., Deng, Z. Z., Yang, Z. Y., et al. (2025). Value of expression profile of mitochondrial ribosomal large subunit protein 13/BCL2-related protein A1/TP53 apoptosis-inducing protein 1 in serum in predicting chemotherapy response of triple-negative breast cancer and its immune regulatory mechanism. Journal of Clinical Medicine in Practice, 29, 33–39.
[12] DiNardo, C. D., Jonas, B. A., Pullarkat, V., et al. (2020). Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. The New England Journal of Medicine, 383(7), 617–629. https://doi.org/10.1056/NEJMoa1932941.
[13] Seymour, J. F., Kipps, T. J., Eichhorst, B., et al. (2018). Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. The New England Journal of Medicine, 378(12), 1107–1120. https://doi.org/10. 1056/NEJMoa17139 76.
[14] Choudhary, G. S., Al-Harbi, S., Mazumder, S., et al. (2015). MCL-1 and BCL-XL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death & Disease, 6(11), e1593. https://doi.org/ 10.1038/ cddis. 2015. 343.
[15] Rahmani, M., Nkwocha, J., Hawkins, E., et al. (2018). Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Research, 78(11), 3075–3086. https://doi.org/10.1158/0008-5472.CAN-17-3332.
[16] Bojarczuk, K., Wienand, K., Ryan, J. A., et al. (2019). Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood, 133(1), 70–80. https://doi.org/10.1182/blood-2018-06-859916.
[17] Blombery, P., Anderson, M. A., Gong, J. N., et al. (2019). Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discovery, 9(3), 342–353. https://doi.org/10.1158/2159-8290.CD-18-1199.
[18] Zhang, Q., Riley-Gillis, B., Han, L., et al. (2022). Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy, 7(1), 51. https://doi.org/10.1038/s41392-022-00881-7.
[19] Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., et al. (2017). From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nature Reviews Drug Discovery, 16, 273–284. https://doi.org/10.1038/nrd.2016.253.
[20] Campbell, K. J., & Tait, S. W. G. (2018). Targeting BCL-2 regulated apoptosis in cancer. Open Biology, 8(5), 180002. https://doi.org/10.1098/rsob.180002.
[21] DiNardo, C. D., Pratz, K. W., Letai, A., et al. (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study. The Lancet Oncology, 19(2), 216–228. https://doi.org/10. 1016/ S1470-2045(17)30809-5.
[22] Lasater, E. A., Amin, D. N., Bannerji, R., et al. (2023). Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. American Journal of Hematology, 98(4), 449–463. https://doi.org/10.1002/ajh.26887.
[23] Bose, P., Gandhi, V., & Konopleva, M. (2017). Pathways and mechanisms of venetoclax resistance. Leukemia & Lymphoma, 58(9), 1–17. https://doi.org/10.1080/10428194.2016.1273394.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
